PURPOSE: The most aggressive form of skin cancer is the malignant melanoma. Because of its high metastatic potential the early detection of primary melanoma tumors and metastases using non-invasive PET imaging determines the outcome of the disease. Previous studies have already shown that benzamide derivatives, such as procainamide (PCA) specifically bind to melanin pigment. The aim of this study was to synthesize and investigate the melanin specificity of the novel (68)Ga-labeled NODAGA-PCA molecule in vitro and in vivo using PET techniques. METHODS: Procainamide (PCA) was conjugated with NODAGA chelator and was labeled with Ga-68 ((68)Ga-NODAGA-PCA). The melanin specificity of (68)Ga-NODAGA-PCA was tested in vitro, ex vivo and in vivo using melanotic B16-F10 and amelanotic Melur melanoma cell lines. By subcutaneous and intravenous injection of melanoma cells tumor-bearing mice were prepared, on which biodistribution studies and small animal PET/CT scans were performed for (68)Ga-NODAGA-PCA and (18)FDG tracers. RESULTS: (68)Ga-NODAGA-PCA was produced with high specific activity (14.9±3.9 GBq/µmol) and with excellent radiochemical purity (98%<), at all cases. In vitro experiments showed that (68)Ga-NODAGA-PCA uptake of B16-F10 cells was significantly (pâ¤0.01) higher than Melur cells. Ex vivo biodistribution and in vivo PET/CT studies using subcutaneous and metastatic tumor models showed significantly (pâ¤0.01) higher (68)Ga-NODAGA-PCA uptake in B16-F10 primary tumors and lung metastases in comparison with amelanotic Melur tumors. In experiments where (18)FDG and (68)Ga-NODAGA-PCA uptake of B16-F10 tumors was compared, we found that the tumor-to-muscle (T/M) and tumor-to-lung (T/L) ratios were significantly (pâ¤0.05 and pâ¤0.01) higher using (68)Ga-NODAGA-PCA than the (18)FDG accumulation. CONCLUSION: Our novel radiotracer (68)Ga-NODAGA-PCA showed specific binding to the melanin producing experimental melanoma tumors. Therefore, (68)Ga-NODAGA-PCA is a suitable diagnostic radiotracer for the detection of melanoma tumors and metastases in vivo.
In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA).
利用新型放射性示踪剂(68)Ga-NODAGA-普鲁卡因胺(PCA)对实验性黑色素瘤肿瘤进行体内成像
阅读:6
作者:Kertész István, Vida András, Nagy Gábor, Emri Miklós, Farkas Antal, Kis Adrienn, Angyal János, Dénes Noémi, Szabó Judit P, Kovács Tünde, Bai Péter, Trencsényi György
| 期刊: | Journal of Cancer | 影响因子: | 3.200 |
| 时间: | 2017 | 起止号: | 2017 Feb 25; 8(5):774-785 |
| doi: | 10.7150/jca.17550 | 研究方向: | 肿瘤 |
| 疾病类型: | 黑色素瘤 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
